



## **Inviragen Recognized by “Colorado Companies to Watch” Program**

**Fort Collins, Colorado**

**18 June 2010**

Inviragen has been named a Colorado Companies to Watch award winner for 2010. Now in its second year, the Colorado Companies to Watch program attracted over 420 nominees for the award. The award recognizes second-stage enterprises that are headquartered in Colorado, privately held, have six to 99 employees, and generate \$750,000 to \$50M in sales.

Inviragen, an international vaccine research and development company, has its headquarters in Fort Collins and operations in Madison, Wisconsin and Singapore. The company develops life-saving vaccines to protect against emerging infectious diseases worldwide. The first human clinical trial of Inviragen’s vaccine designed to protect against dengue fever was initiated in May.

Founded in 2005, the company has experienced positive year-over-year employee and revenue growth. Beginning with one staff member, Inviragen has grown to 30 employees. Revenues have continued to grow as well and Inviragen recently placed second on the Mercury 100 list, an annual ranking of the region’s fastest growing private companies.

“By raising both grant and investor financing for its vaccine research and development efforts, Inviragen has been able to grow its revenues and advance its vaccines from the research bench to clinical testing,” said Dr. Dan Stinchcomb, Inviragen CEO. “Being named a Colorado Company to Watch is a tribute to the dedication of our employees to the goal of developing vaccines that will improve public health worldwide.”

Colorado Companies to Watch is organized by the Colorado Office of Economic Development and International Trade in association with economic development councils throughout the state. The panel of independent judges selected companies based on such factors as employee or sales growth, entrepreneurial leadership and sustainable competitive advantage.

“Our state’s strong entrepreneurial spirit is helping to move Colorado forward,” Gov. Bill Ritter said. The Colorado Companies to Watch program is a great way to show appreciation of our home-grown Colorado businesses. These second-stage companies have helped to grow our economy even during tough times.”

### **About Inviragen**

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever, a disease that threatens 3.6 billion people across the globe. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclinical research stages include a low-cost human papilloma virus vaccine, a chikungunya vaccine, and vaccines to protect against new forms of influenza for global health markets. Inviragen has offices and laboratories in Fort Collins, Colorado, Madison, Wisconsin and Singapore. Please see [www.inviragen.com](http://www.inviragen.com) for more details.